ArticlePsycho-oncology2026
Neurotrophic-Inflammatory Imbalance and Cognitive Decline After Adjuvant Chemotherapy in Colon Cancer: A Prospective Cohort Study.
Article in Psycho-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCancer-related cognitive impairment (CRCI) is a prevalent yet underrecognized complication among colon cancer survivors that adversely affects quality of life and psychological well-being. Emerging evidence suggests that neurotrophic dysregulation and systemic inflammation may contribute to chemotherapy-related neurotoxicity; however, longitudinal biomarker-based data remain limited.
methodsIn this prospective cohort study, 127 patients with resected colon cancer were evaluated at baseline and at the 6-month follow-up. Of these, 83 received adjuvant chemotherapy and 44 underwent postoperative surveillance alone. Cognitive performance (MoCA), depressive symptoms (HADS-D), and peripheral neuropathy (CIPN20) were assessed alongside serum brain-derived neurotrophic factor (BDNF) levels and systemic inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein-to-albumin ratio (CAR). Linear mixed model and logistic regression analyses were performed to identify factors associated with cognitive decline.
resultsAdjuvant chemotherapy was associated with significant reductions in MoCA scores and serum BDNF levels (both p < 0.001), particularly among patients receiving the oxaliplatin-based XELOX regimen. Greater longitudinal reductions in BDNF (ΔBDNF) were independently associated with higher odds of CRCI (OR = 0.749 per 10 ng/mL increase in ΔBDNF, 95% CI: 0.658-0.854, p < 0.001). The model including ΔBDNF showed higher apparent discrimination than the corresponding model without ΔBDNF (AUC = 0.929 vs. 0.812).
conclusionLongitudinal reductions in serum BDNF were independently associated with CRCI among patients receiving adjuvant chemotherapy. These findings support a potential role for neurotrophic dysregulation in chemotherapy-related cognitive decline and highlight the need for further validation studies evaluating BDNF as a candidate biomarker for CRCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.